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Primary cardiac spindle cell sarcomas are extremely rare and have poor prognosis. Complete surgical resection
represents the only treatment option proven to work. We report a case of a 28-year-old man who was referred to
our cardiothoracic unit with a right ventricular mass extending to the main pulmonary artery with a provisional
diagnosis of a thrombus or a right ventricular myxoma. He sought medical attention after experiencing shortness
of breath, cough, chest pain, abdominal pain and bilateral leg swelling for about 6 weeks. Two dimensional
transthoracic echocardiogram showed a mass arising from the right ventricle and extending into the main
pulmonary artery; findings that were confirmed with contrast chest CT scan.
He underwent extensive resection of the mass and had uneventful postoperative period with immediate
symptomatic relieve. He is on adjuvant chemotherapy using vincristine, adriamycin and cyclophosphamide (VAC).
Right ventricular sarcoma is a very rare cause of right sided heart failure, a very aggressive tumour whose only
chance of successful treatment is complete surgical excision.
Keywords: Right ventricle, Spindle cell sarcoma, MyxomaBackground
Primary cardiac tumours are rare with a reported inci-
dence of 0.017-0.019 [1]. Most cardiac tumours are
metastases with majority having a pulmonary source
[2]. Seventy-five percent of primary cardiac tumours
are benign with close to half being myxomas [1,3].
Twenty-five percent are malignant with 95% of these
being reported as sarcomas [1]. The most common sar-
coma is angiosarcoma (34%) and undifferentiated sarcoma
second at 24%. Others include rhabdomyosarcoma, osteo-
sarcoma, synovial sarcoma and leiomyosarcoma [1]. The
least reported cardiac tumours are spindle cell sarcomas
[1,4-6].
These tumours are rare and produce non-specific
symptoms. They are thus often difficult to diagnose pre-
operatively and they can be missed. Use of echocardio-
gram (transesophageal echocardiogram is more sensitive
than transthoracic Echo), CT scan and cardiac MRI
makes preoperative diagnosis possible. In most cases,
the provisional diagnosis is a benign myxoma and the
suspicion of sarcomas is only made intraoperatively due* Correspondence: almuturi@gmail.com
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unless otherwise stated.to the tendency of the tumour to be invasive. Due to rar-
ity of these tumours, there is no consensus on effective
adjuvant therapy.Case presentation
A 28 year old mechanic from rural Kenya, was referred
to our unit with a provisional diagnosis of right ventricu-
lar tumour, favouring either a thrombus or myxoma. He
sought medical attention after experiencing shortness of
breath, cough, chest pain, abdominal pain and bilateral
leg swelling for 6 weeks. He also reported unexplained
weight loss (8 kg), fever and night sweats. He had been
admitted two weeks earlier at a peripheral hospital and
treated for pneumonia, but the symptoms persisted.
Tests for tuberculosis were negative. There is no history
of asthma in the family. He doesn’t smoke or take alco-
hol. He is single and lives with his parents.
Physical examination revealed marked bilateral pedal
oedema, distended neck veins, and tender hepatomegaly.
The laboratory tests showed markedly elevated liver
enzymes; AST 664 (5–42) IU/L and ALT 224 5–42) IU/L
with other blood tests being within normal limits. Based
on these features of right-sided heart failure and suspicion
of a thrombus in the right ventricle, he was started onThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tomatic improvement.
A chest x-ray showed cardiomegaly and minimal right
sided pleural effusion. The ECG revealed sinus tachycar-
dia and right ventricular hypertrophy. Two Dimensional
transthoracic echocardiogram showed a mass arising
from the right ventricle and extending into the main
pulmonary artery, small pericardial effusion and a right
sided pleural effusion. Contrast Chest CT scan confirmed
the Echo findings (Figure 1).
Intraoperatively we found, normal appearing pericar-
dium, and minimal pericardial effusion. Right ventriculot-
omy was performed after going on cardiopulmonary
bypass, we found a whitish yellow lobulated, friable mass
that appeared to arise from the septal leaflet of the tricus-
pid valve, with a wide base and filling the entire ventricu-
lar chamber with diffuse infiltration of the ventricular
walls and extending into and nearly occluding the main
pulmonary artery trunk, without adhering to it.
With pulmonary artery cross clamp on, the mass was
gently delivered from the pulmonary artery and dis-
sected off the RV and the tricuspid valve. The tricuspid
valve was then repaired. Due to the diffuse infiltrating
nature of the tumour, resection with margins was not
feasible. The patient was nursed in ICU and discharged
to the general ward on the third postoperative day. Re-
peat echocardiogram in the immediate postoperative
period showed moderate tricuspid regurgitation, mild
pulmonary hypertension and a mild right-sided pleural
effusion.
He was put on diuretics; frusemide and spirinolactone
and he is currently asymptomatic. Definitive histopath-
ology of the mass revealed a high-grade spindle cell sar-
coma. Immunohistochemical tests showed the tumour
only had patchy positivity for AE1/AE3 and negative for
the following markers: SMA, Desmin, CD34, S100, EMA,
and CD99. Staining for CD117 was not performed.Figure 1 Preoperative echocardiogram showing right ventricular
mass.He is undergoing adjuvant chemotherapy using VAC
regimen. He received 2 mg of Vincristine as the total
dose per course, Adriamycin at 70 mg/m2, and Cyclo-
phosphamide at 600 mg/m2, administered as intravenous
bolus infusion. He received six courses of adjuvant
chemotherapy at 21 days interval.
Discussion
This patient was first admitted with a diagnosis of a
thrombus in the right ventricle and started on anticoagu-
lation and ant failure regime. After ten days of treatment
without much improvement the cardiothoracic team was
consulted and possibility of a heart tumour was encour-
aged, a repeat two-dimensional transthoracic echocardio-
gram still showed a mass in the right ventricle.
Our facility doesn’t have capability to perform trans-
esophageal echocardiogram which would better define
the intracardiac mass. The patient went to surgery with
a provisional diagnosis of right ventricular myxoma or a
thrombus, these being the commoner intracardiac tu-
mours. It was not possible to achieve tumour free margins
due to the extensive infiltration of the tumour into the
right ventricular walls. The post operative echocardiogram
showed marked improvement in cardiac output and right
ventricular function.
The patient was started on adjuvant chemotherapy,
using the VAC regimen, which in our set up is the af-
fordable treatment option for sarcomas. This patient is
being followed up at our cardiothoiracic outpatient clinic
every three months, oncology unit and cardiology clinic.
In view of the intraoperative findings and the chemo-
therapy regimen he is on that includes Adriamycin, an
echocardiogram will be performed at the end of each
treatment cycle to reassess the functional status of the
heart. The most recent echocardiogram done three
months after surgery, showed mild tricuspid regurgita-
tion, he remains symptom free and he is off ant failure
drugs.
The earliest report of tumour in the heart dates back
to mid 16th century, by Colombus [7]. The commonest
cardiac sarcomas are angiosarcomas, followed by malig-
nant fibrous histiocytomas (MFH). The angiosarcomas
have predilection for the right side of the heart with the
MFHs favouring the left [3,4] Cardiac spindle cell
sarcomas are tumours of mesenchymal origin, more
commonly affecting the large blood vessels. They are
extremely rare in the heart, with only four cases re-
ported so far [4-6]. Echocardiography by transthoracic
or preferably transesophageal route is easy to perform,
rapid and inexpensive tool to identify intracardiac
masses. Transesophageal echocardiography (TEE) pro-
vides better resolution, as it allows for use of higher-
frequency transducers. However, TEE provides limited
soft-tissue characterization and visualization of the
Muturi et al. Journal of Cardiothoracic Surgery  (2015) 10:46 Page 3 of 4mediastinum [2]. CT and MRI scan of chest and abdo-
men complement echocardiography [8].
Unlike echocardiography, CT and MRI have the ad-
vantage of showing the extra cardiac extent of tumour
and presence of metastases, myocardial infiltration,
compression of cardiac chambers along with pericardial
and great vessel involvement [8]. Cardiac MRI (CMRI)
is useful to assess tumour volume, tumour burden, me-
diastinal invasion and response to therapy. The limita-
tions of CMRI include cost and dependence on regular
electrocardiographic rhythms and cardiac gating [8].
Chest x-ray though not diagnostic may show cardio-
megaly, infiltrates suggestive of pulmonary oedema due
to congestive cardiac failure, pleural effusion, lung nod-
ules, cardiac mass or left hemi diaphragm paralysis [2].
Electrocardiogram is usually non-diagnostic being normal
or may show non-specific changes such as conduction
block, right ventricular hypertrophy, atrial fibrillation,
paroxysmal atrial tachycardia etc. [2]. Where expertise
exists and condition of the patient permits, transvenous
end myocardial biopsy is helpful to yield a histological
confirmation before operation [9].
These tumours are highly aggressive, rapidly infiltrating
all the layers of the heart and metastasize rapidly. At the
time of presentation up to 80% have evidence of metastasis
[10]. The prognosis of cardiac primary spindle cell sarco-
mas is poor because these tumours are highly aggressive
with reported mean survival of approximately 3 months to
1 year. Survival of up to 11 years has been reported [6].
Cardiac tumours can cause significant morbidity and mor-
tality because of the delicate structures involved [4].
The effects of a cardiac tumour depend on its anatom-
ical location in the heart, size, invasiveness, friability, and
the rate of growth with the most important factor affect-
ing the prognosis of these tumours being the anatomical
location in the heart (intracavitary versus intra/extramyo-
cardial growth) [4]. Surgery with negative resection mar-
gins is the only proven successful treatment so far but
complete tumour resection is only possible in less than
50% of patients [4]. It has been shown that patients who
undergo surgery with negative resection margins have two
times the life expectancy of those who complete surgical
resection is not feasible [11], this shows that early diagno-
sis and timely treatment have an impact on treatment suc-
cess and prognosis. Additionally surgery also has a role in
palliative resections for relief of symptoms, biopsy to con-
firm diagnosis or repeated resections. Though the initial
results of surgery are encouraging their long-term survival
remains poor mostly due to local or systemic recurrence.
Never the less surgery has been shown to prolong the sur-
vival and improve the quality of life [11].
When spindle cell sarcoma arises in the heart, the
differential diagnosis includes angiosarcoma or synovial
sarcoma. Spindle cell sarcomas usually show positiveimmunoreactivity for vimentin, osteopontin, and MDM2
[12,13]. Variable positivity may be observed for alpha
smooth muscle actin, CD117, CD68, p53, and bcl-2.
Occasionally, the tumour has some positive staining with
antibodies against desmin. CD31, CD34, and Factor VIII
are typically negative. The role of chemotherapy or radio-
therapy in the treatment of primary cardiac sarcoma has
not proven to be beneficial [14], though there are some re-
ports of adriamycin [14] and doxorubicin [15] showing
some improvement in survival. Poor tolerance of radiation
by the heart has limited the use of radiotherapy. Though it’s
role has not been proven, radiotherapy has been used for
treatment of positive margins after resections, palliation of
aggressive localized disease and local recurrences [4].
Conclusion
Cardiac sarcomas remain a challenge to treat partly due
to their rarity and also because of the aggressive nature
of these tumours. Its diagnosis can be challenging due to
the nonspecific nature of presentation. In our setup two-
dimensional echocardiography is available and this tool
aids in quick evaluation of the heart enabling the genesis
of a prompt provisional diagnosis. Surgery remains the
mainstay of treatment. Keeping in mind that adjuvant
therapy has poor response the cardiac surgeon needs to
strike a balance between obtaining adequate tumour free
margin and leaving behind a functioning heart.
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